HKMPY (Hikma Pharmaceuticals) FFO


HKMPY Hikma Pharmaceuticals PLC HKMPY
87 GF Score
Price $41.23
GF Value $56.71
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

HKMPY
87GF Score
Hikma Pharmaceuticals PLC HKMPY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hikma Pharmaceuticals (HKMPY) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $41.23 is trading 27.3% below its estimated GF Value™ of $56.71. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPY:

  • FFO:
  • GF Value™: $56.71 vs. price of $41.23 (27.3% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the HKMPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score

Get the complete analysis for HKMPY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.23
Price
$56.71
GF Value